Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$399.3M
422M shares
52-week range
$0.84 – $2.38
10% from low
Sector
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
Exchange
NASDAQ
CS
Borrow rate
32.22%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $226.3M | $398.8M | $546.6M | $475.7M | $333.3M | $297.1M | $269.0M | $284.6M |
| Cost of revenue | $137.4M | $430.5M | $479.7M | $663.1M | $396.8M | $216.3M | $189.5M | $214.9M |
| Gross profit | $88.9M | −$31.7M | $67.0M | −$187.4M | −$63.5M | $80.9M | $79.5M | $69.7M |
| Gross margin | 39.3% | -7.9% | 12.2% | -39.4% | -19.1% | 27.2% | 29.6% | 24.5% |
| R&D | $15.2M | $61.8M | $57.6M | $32.3M | $21.7M | $4.6M | $1.9M | $0 |
| Operating income | −$615.2M | −$1.67B | −$1.24B | −$1.02B | −$2.63B | −$228.7M | −$117.1M | −$73.1M |
| EBITDA | −$567.1M | −$1.38B | −$449.7M | −$53.0M | −$2.88B | −$312.8M | −$479.3M | −$188.2M |
| Net income | −$736.3M | −$1.32B | −$1.74B | −$310.0M | −$3.28B | −$657.3M | −$598.1M | −$262.9M |
| Net margin | -325.3% | -331.3% | -319.2% | -65.2% | -983.7% | -221.2% | -222.4% | -92.4% |
| EPS (diluted) | -1.99 | -3.90 | -4.45 | -7.70 | -70.70 | -8.79 | -5.53 | -0.88 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $245M | $-0.21 | $-0.33–$-0.12 | 2 |
| 2028 | $266M | $-0.18 | $-0.19–$-0.17 | 1 |
| 2029 | $286M | $-0.06 | $-0.06–$-0.05 | 1 |
| 2030 | $305M | $-0.04 | $-0.04–$-0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
www.canopygrowth.comNo one on the platform currently holds CGC.
No tracked institution reports a position in CGC as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-12-20 | 1-for-10reverse |
No one on the platform has traded CGC yet.
| $496M |
| — |
| DHDefinitive Healthcare Corp. | $0.66 | +5.10% | $70M | — |
| IRWDIronwood Pharmaceuticals, Inc. | $4.13 | +7.55% | $680M | — |
Source: Financial Modeling Prep · peers by sector/industry
$CGC $TLRY Another positive milestone for the cannabis sector. Virginia has officially approved adult use cannabis sales through its state budget, making it law. More states continue moving forward, and the momentum for cannabis reform keeps building. 🌿📈
View on StockTwits ↗$CGC $TLRY Don’t just focus on the headlines. Focus on what was added to the official record today. DEA and FDA representatives highlighted medical benefits and relative safety. That’s a positive foundation for Schedule III. 📈
View on StockTwits ↗@Merlintrader Don't put $TLRY, $CGC and $MSOS in the same camp. Two CANADIAN weed companies with NO US weed sales and one ETF full of ALL AMERICAN weed stocks selling ... WEED. S3 matters to American weed companies, who will start taking business in Europe from those who previously had a monopoly on the market.
View on StockTwits ↗$CGC $TLRY For those who don’t know, Kevin Sabet is one of the biggest opponents of cannabis reform and DEA rescheduling in the U.S. The fact he’s already complaining after today’s hearing is, in my opinion, a good sign for the pro rescheduling side. 👀📈
View on StockTwits ↗$CGC $TLRY Another bullish signal 👀 House Speaker Mike Johnson reportedly won’t block a full House vote on SAFE Banking if the majority of Republicans support it. One more political hurdle may be coming off the table.
View on StockTwits ↗$CGC this is the type of price action that is healthy. Falling in lower volume and up in higher volume. This stock is basically trading at cash. Intrinsic value is over $3. Just going to keep accumulating. Added more today. Next purchase Friday.
View on StockTwits ↗$CGC over 6% in a day someone is tired of it going down vol jumped to 5.M
View on StockTwits ↗$CGC Got out of here a bit and into SLS but taking some of my 125% profits and getting back in here for maybe 10,000 shares. Its time has come now
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 0.3× sales vs its 6.6× historical median P/S.
Fair value ≈ $22.33 · price $0.99 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.